{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058415","form_type":"8-K","ticker":null,"cik":"0001012477","company_name":"AVADEL PHARMACEUTICALS PLC","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.872008+00:00","generated_at":"2026-06-02T08:24:37.805639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Avadel reports Q1 LUMRYZ revenue $27.2M; patient starts up 70%; pediatric sNDA accepted","bullets":["Q1 2024 net product revenue of $27.2M from LUMRYZ; gross profit $25.7M.","Net loss narrowed to $27.3M ($0.30 per share) vs. $30.8M ($0.48) in Q1 2023.","Over 1,700 patients initiated therapy (up >70% from Dec 31); RYZUP enrollments 2,800 (up ~50%).","FDA accepted sNDA for LUMRYZ in pediatric narcolepsy; PDUFA date set for Sept 7, 2024.","On track to enroll first patient in Phase 3 idiopathic hypersomnia trial in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058415","json":"https://secwatch.observer/filing/0001104659-24-058415.json","markdown":"https://secwatch.observer/filing/0001104659-24-058415.md","text":"https://secwatch.observer/filing/0001104659-24-058415.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924058415/0001104659-24-058415-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924058415/tm2413641d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T08:24:37.805639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13fe55bfd64a2bc7403ca1c051b91e2289a1949d","claim":"AVADEL PHARMACEUTICALS PLC reported the quarter ended March 31, 2024 results: revenue $27.2 million, net income $27.3 million, EPS ($0.30) per diluted share.","evidence_excerpt":"--- EX-99.1 2 tm2413641d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results -- Generated $27.2 million in net revenue from sales of LUMRYZTM -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1012477/000110465924058415/0001104659-24-058415-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$27.2 million"},{"label":"Net income","value":"$27.3 million"},{"label":"EPS","value":"($0.30) per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}